Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.83 |
| ▸ | NPC1 | O15118 | 9/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315103 | 0.89 | NPC1 (0.76) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL16589423 | 0.87 | RAB9A (0.83) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL29366822 | 0.86 | RAB9A (0.89) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL997866 | 0.86 | RAB9A (0.89) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL14859988 | 0.85 | RAB9A (0.79) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10978860 | 0.85 | RAB9A (0.86) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL16583895 | 0.85 | RAB9A (0.86) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL5011704 | 0.85 | RAB9A (0.86) | RAB9ANPC1MEN1KMT2AF2 | |
| SCHEMBL7189774 | 0.84 | RAB9A (0.86) | RAB9ANPC1MEN1KMT2AF2 | |
| Hydrochloric Acid SCHEMBL27681799 | 0.84 | RAB9A (0.86) | RAB9ANPC1MEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104035-A1 | SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 英矽智能科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-109053558-B | Synthesis method of N-heterocyclic amide derivative | 贵州大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-113735850-A | Synthesis method of 1,2, 4-triazole compound | 河南师范大学 | 2021-12-03 | — | — | CN | disclosed |
| WO-2021111465-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACALABRUTINIB AND ITS INTERMEDIATES | NATCO PHARMA LIMITED (IN) | 2021-06-10 | — | — | WO | disclosed |
| US-10800787-B2 | Process for the preparation of acalabrutinib | APOTEX INC. (CA) | 2020-10-13 | — | — | US | disclosed |
| EP-3392240-B1 | USE OF N-(PYRIDIN-2-YL)-AMIDE AND PHENYL-UREA DERIVATIVES FOR TERAHERTZ TAGGING APPLICATIONS | COUNCIL SCIENT IND RES (IN) | 2020-06-03 | — | — | EP | disclosed |
| US-20200048264-A1 | Processes for the Preparation of Acalabrutinib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2020-02-13 | — | — | US | disclosed |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| US-10464929-B2 | Organic molecules for terahertz tagging applications | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-11-05 | — | — | US | disclosed |
| WO-2019056466-A1 | BRUTON TYROSINE KINASE INHIBITOR | 南京亘泰医药技术有限公司 | 2019-03-28 | — | — | WO | disclosed |
| US-8647528-B2 | Water absorbing agent and production method thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8455513-B2 | Kinase inhibitors; anticarcinogenic agents; obesity, glaucoma; N-(4-(3-(isoquinolin-6-ylamino)-3-oxopropyl)phenyl)-4-methoxybenzamide | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455647-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130137721-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100270501-A1 | Water absorbing agent and production method thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137721-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | RAB9A 568/4885NPC1 510/4885MEN1 3210/4885 |
| US-20200048264-A1 | Processes for the Preparation of Acalabrutinib and Intermediates Thereof | ACACB, ACACA, BTK | RAB9A 982/4885NPC1 3423/4885MEN1 2363/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | RAB9A 94/4885NPC1 77/4885MEN1 3930/4885 |
| US-10464929-B2 | Organic molecules for terahertz tagging applications | WIZ, CRYZ, NAA15 | RAB9A 4203/4885NPC1 4342/4885MEN1 2255/4885 |
| US-10800787-B2 | Process for the preparation of acalabrutinib | ACACA, ACACB, BTK | RAB9A 1040/4885NPC1 3622/4885MEN1 2512/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | RAB9A 730/4885NPC1 735/4885MEN1 2940/4885 |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | RAB9A 895/4885NPC1 1786/4885MEN1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.